| 2001 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Germany |
65 |
| 2002 |
Apheresis |
Allogeneic |
Primary myelofibrosis |
Hematology |
2024 |
Standard Therapy |
Germany |
55 |
| 2003 |
Apheresis |
Autologous |
Amyloid Light-Chain Amyloidosis |
Hematology |
2024 |
Standard Therapy |
Germany |
55 |
| 2004 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Germany |
61 |
| 2005 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Germany |
65 |
| 2006 |
Apheresis |
Autologous |
Epstein–Barr Virus Positive Diffuse Large B-Cell Lymphoma |
Hematology |
2024 |
Standard Therapy |
Germany |
63 |
| 2007 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Germany |
69 |
| 2008 |
Apheresis |
Autologous |
Angioimmunoblastic T-cell lymphoma |
Hematology |
2024 |
Standard Therapy |
Germany |
58 |
| 2009 |
Apheresis |
Allogeneic |
Acute lymphoblastic leukemia |
Hematology |
2024 |
Standard Therapy |
Germany |
19 |
| 2010 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Germany |
66 |
| 2011 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Germany |
61 |
| 2012 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Canada |
16 |
| 2013 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Germany |
61 |
| 2014 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2024 |
Standard Therapy |
USA |
75 |
| 2015 |
Apheresis |
Allogeneic |
Myelofibrosis Myeloid Metaplasia |
Hematology |
2024 |
Standard Therapy |
USA |
62 |
| 2016 |
Apheresis |
Allogeneic |
Myelodysplastic Disorders |
Hematology |
2024 |
Standard Therapy |
France |
66 |
| 2017 |
Apheresis |
Allogeneic |
B-Cell Lymphoma |
Hematology |
2024 |
Standard Therapy |
Canada |
70 |
| 2018 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Italy |
60 |
| 2019 |
Apheresis |
Allogeneic |
Myeloma Multiplex |
Hematology |
2024 |
Standard Therapy |
Poland |
57 |
| 2020 |
Apheresis |
Allogeneic |
Diffuse large B-cell lymphoma |
Hematology |
2024 |
Standard Therapy |
Poland |
17 |
| 2021 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
48 |
| 2022 |
Apheresis |
Allogeneic |
Chronic lymphocytic leukemia |
Hematology |
2024 |
Standard Therapy |
Germany |
63 |
| 2023 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
65 |
| 2024 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2024 |
Standard Therapy |
USA |
64 |
| 2025 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2024 |
Standard Therapy |
USA |
76 |
| 2026 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
44 |
| 2027 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
62 |
| 2028 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
NETHERLANDS |
25 |
| 2029 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2024 |
Standard Therapy |
USA |
42 |
| 2030 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2024 |
Standard Therapy |
CROATIA |
66 |
| 2031 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2024 |
Standard Therapy |
USA |
70 |
| 2032 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2024 |
Standard Therapy |
Switzerland |
68 |
| 2033 |
Apheresis |
Allogeneic |
Chronic Myelomonocytic Leukaemia |
Hematology |
2024 |
Standard Therapy |
NETHERLANDS |
62 |
| 2034 |
Apheresis |
Allogeneic |
Chronic Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
USA |
58 |
| 2035 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Germany |
62 |
| 2036 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Belarus |
54 |
| 2037 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Spain |
9 |
| 2038 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
66 |
| 2039 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
France |
67 |
| 2040 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
France |
54 |
| 2041 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2024 |
Standard Therapy |
South Africa |
54 |
| 2042 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Germany |
60 |
| 2043 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Sweden |
60 |
| 2044 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2024 |
Standard Therapy |
Spain |
67 |
| 2045 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Germany |
66 |
| 2046 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Germany |
53 |
| 2047 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Germany |
65 |
| 2048 |
Apheresis |
Autologous |
Non-Hodgkin Lymphoma, rezidiv |
Hematology |
2024 |
Standard Therapy |
Germany |
64 |
| 2049 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Germany |
57 |
| 2050 |
Apheresis |
Allogeneic |
Acute myeloid leukemia |
Hematology |
2024 |
Standard Therapy |
Germany |
66 |
| 2051 |
Apheresis |
Allogeneic |
Acute lymphoblastic leukemia |
Hematology |
2024 |
Standard Therapy |
Germany |
50 |
| 2052 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Germany |
57 |
| 2053 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2024 |
Standard Therapy |
USA |
70 |
| 2054 |
Apheresis |
Allogeneic |
Multiple Organ Dysfunction Syndrome |
Hematology |
2024 |
Standard Therapy |
Germany |
42 |
| 2055 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
USA |
32 |
| 2056 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
USA |
76 |
| 2057 |
Apheresis |
Allogeneic |
Hodgkin Lymphoma |
Hematology |
2024 |
Standard Therapy |
Italy |
63 |
| 2058 |
Apheresis |
Allogeneic |
Early T-cell precursor Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Australia |
43 |
| 2059 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2024 |
Standard Therapy |
USA |
72 |
| 2060 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2024 |
Standard Therapy |
Germany |
72 |
| 2061 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
52 |
| 2062 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
USA |
73 |
| 2063 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2024 |
Standard Therapy |
Poland |
68 |
| 2064 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Italy |
63 |
| 2065 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Czechia |
46 |
| 2066 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
France |
64 |
| 2067 |
Apheresis |
Allogeneic |
Primary Immunodeficiencies |
Hematology |
2024 |
Standard Therapy |
Russia |
7 |
| 2068 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Germany |
68 |
| 2069 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Germany |
62 |
| 2070 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Germany |
48 |
| 2071 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2024 |
Standard Therapy |
USA |
63 |
| 2072 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia |
Hematology |
2024 |
Standard Therapy |
Spain |
58 |
| 2073 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
41 |
| 2074 |
Apheresis |
Allogeneic |
Myelofibrosis Myeloid Metaplasia |
Hematology |
2024 |
Standard Therapy |
USA |
73 |
| 2075 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
15 |
| 2076 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Germany |
65 |
| 2077 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
38 |
| 2078 |
Apheresis |
Allogeneic |
Plasmacytoma |
Hematology |
2024 |
Standard Therapy |
Poland |
46 |
| 2079 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Portugal |
60 |
| 2080 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Portugal |
60 |
| 2081 |
Skeletal Muscle |
Allogeneic – Related |
Duchenne Muscular Dystrophy (DMD) |
Genetic disorder |
2023 |
Experimental Therapy |
Poland |
8 |
| 2082 |
Skeletal Muscle |
Allogeneic – Related |
Duchenne Muscular Dystrophy (DMD) |
Genetic disorder |
2023 |
Experimental Therapy |
Poland |
16 |
| 2083 |
Cord Tissue |
Allogeneic – Related |
Ags (Autism + Epilepsy) |
Neurology |
2023 |
Experimental Therapy |
Poland/Romania |
15 |
| 2084 |
Cord Tissue |
Allogeneic – Related |
Autism |
Neurology |
2023 |
Experimental Therapy |
Romania |
8,5 |
| 2085 |
Cord Tissue |
Autologous |
Autism |
Neurology |
2023 |
Experimental Therapy |
Hungary |
10 |
| 2086 |
Cord Tissue |
Allogeneic – Related |
Autism |
Neurology |
2023 |
Experimental Therapy |
Romania |
4 |
| 2087 |
Cord Tissue |
Allogeneic – Related |
Autism |
Neurology |
2023 |
Experimental Therapy |
Romania |
10 |
| 2088 |
Cord Tissue |
Allogeneic – Related |
Autism |
Neurology |
2023 |
Experimental Therapy |
Romania |
3,2 |
| 2089 |
Cord Tissue |
Autologous |
Cerebral Palsy |
Neurology |
2023 |
Experimental Therapy |
Romania |
2 |
| 2090 |
Cord Tissue |
Allogeneic – Related |
Cerebral Palsy |
Neurology |
2023 |
Experimental Therapy |
Romania |
3 |
| 2091 |
Cord Tissue |
Allogeneic – Unrelated |
Disorders Of Optic Nerve |
Ophthalmology |
2023 |
Experimental Therapy |
Poland |
39,1 |
| 2092 |
Cord Tissue |
Allogeneic – Unrelated |
Gonarthrosis |
Orthopedy |
2023 |
Experimental Therapy |
Poland |
65,1 |
| 2093 |
Cord Tissue |
Allogeneic – Unrelated |
Gonarthrosis |
Orthopedy |
2023 |
Experimental Therapy |
Poland |
50,8 |
| 2094 |
Cord Tissue |
Allogeneic – Unrelated |
Graft Versus Host Disease |
Hematology |
2023 |
Experimental Therapy |
Poland |
8 months |
| 2095 |
Cord Tissue |
Allogeneic – Unrelated |
Graft Versus Host Disease |
Hematology |
2023 |
Experimental Therapy |
Poland |
16,2 |
| 2096 |
Cord Tissue |
Allogeneic – Unrelated |
Internal Damage To The Knee Joint |
Orthopedy |
2023 |
Experimental Therapy |
Poland |
20,8 |
| 2097 |
Cord Tissue |
Allogeneic – Unrelated |
Internal Damage To The Knee Joint |
Orthopedy |
2023 |
Experimental Therapy |
Poland |
49,8 |
| 2098 |
Cord Tissue |
Allogeneic – Unrelated |
Internal Damage To The Knee Joint |
Orthopedy |
2023 |
Experimental Therapy |
Poland |
62,7 |
| 2099 |
Cord Tissue |
Allogeneic – Unrelated |
Internal Damage To The Knee Joint |
Orthopedy |
2023 |
Experimental Therapy |
Poland |
24,1 |
| 2100 |
Cord Tissue |
Allogeneic – Unrelated |
Mucopolysaccharidosis Type Ii |
Hematology |
2023 |
Experimental Therapy |
Poland |
4,7 |